TGFB1 and metabolic dysfunction-associated steatohepatitis: In contrast, chymase inhibitors dramatically attenuate angiotensin II, MMP-9, and TGF-β reduction observed in NASH, subsequently improving steatosis, inflammation, and fibrosis [18,19,20].